EU Approves Monthly Fabry Treatment, Cutting Infusions in Half

Imagine spending every other week of your entire life in a clinic for hours-long infusions. For adults with Fabry disease, that exhausting reality just got easier.

The European Union approved a new monthly dosing option for Elfabrio, a treatment for Fabry disease, cutting the number of required infusions in half for eligible patients. Adults whose condition is stable on enzyme replacement therapy can now receive the treatment once every four weeks instead of every two weeks.

Fabry disease is a rare genetic condition where the body can't properly break down certain fatty molecules. Without treatment, these molecules build up and damage the kidneys, heart, and nervous system. Enzyme replacement therapy has been the main treatment for over 20 years, but it requires regular infusions that become a constant part of life.

The approval from the European Commission came after clinical trials showed the monthly schedule was safe and effective for patients with stable disease. The BRIGHT study tracked 30 adults who switched to the less frequent regimen and found it worked just as well.

"Because Fabry disease requires lifelong treatment, the cadence of therapy inevitably becomes part of everyday life for patients and caregivers," said Giacomo Chiesi, executive vice president at Chiesi Global Rare Diseases. The company developed Elfabrio alongside Protalix Biotherapeutics.

The Ripple Effect

This change means more than just fewer hospital visits. Families can plan vacations without working around infusion schedules. Patients can focus on careers without taking time off work every other week. Healthcare systems can serve more people with the same resources.

Mary Pavlou, president of the Fabry International Network, called the approval meaningful for patients across more than 50 countries her organization serves. "This approval allows for fewer infusion visits, helping reduce the ongoing burden on patients and families, allowing them to spend more time living their lives beyond treatment," she said.

The enzyme in Elfabrio was specifically designed to stay active longer in the bloodstream, making monthly dosing possible. While the every-two-week schedule remains the only option for patients whose disease isn't stable and for all patients in the United States, the European approval opens the door for similar changes elsewhere.

For thousands of families managing Fabry disease, this approval means treatment finally fits around life instead of the other way around.